Literature DB >> 8393843

Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma.

K Yamashita1, S Yonezawa, S Tanaka, H Shirahama, K Sakoda, K Imai, P X Xing, I F McKenzie, J Hilkens, Y S Kim.   

Abstract

The expression of mucin carbohydrates [Tn, sialosyl-Tn(STn), and T antigens] and core proteins [MUCI-apomucin-related antigen (ARA) and MUC2-ARA] was examined immunohistochemically in tissues from 40 patients with hepatolithiasis and 26 patients with intrahepatic bile-duct carcinoma. Tn and STn antigens were expressed in most of the carcinomas, and were also often expressed in the atypical bile-duct epithelium of the patients with hepatolithiasis or carcinoma, whereas they were rarely or never expressed in the normal bile duct, suggesting that they are effective tumor markers. T antigen was less useful as a marker for intrahepatic bile-duct carcinoma or the atypical epithelium, because it was expressed in normal bile-duct of some cases. Regarding the expression of ARAs in the carcinomas, non-invasive bile-duct cyst adenocarcinomas with favorable prognosis either expressed no MUCI-ARA with [DF3(-), MUSEII(-) and 139H2(-)] staining pattern or expressed MUCI-ARA with [DF3(-), MUSEII(+) and 139H2(+)] staining pattern. However these tumors often expressed MUC2-ARA with [anti-MRP(+) and CCP58(+)] staining pattern. In contrast, most invasive non-papillary cholangiocarcinomas with poor prognosis expressed MUCI-ARA with [DF3(+), MUSEII(+) and 139H2(+)] staining pattern, but expressed no MUC2-ARA with [anti-MRP(-) and CCP58(-)] staining pattern. These results suggests that different apomucins are produced by bile-duct cystadenocarcinomas and cholangiocarcinomas with differing prognosis. Furthermore, expression of Tn and STn antigens is a useful indicator of malignancy in the intrahepatic duct.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393843     DOI: 10.1002/ijc.2910550116

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

2.  Biliary epithelial expression of MUC1, MUC2, MUC3 and MUC5/6 apomucins during intrahepatic bile duct development and maturation. An immunohistochemical study.

Authors:  M Sasaki; Y Nakanuma; T Terada; Y S Kim
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

3.  Precursor lesions of pancreatic cancer.

Authors:  Suguru Yonezawa; Michiyo Higashi; Norishige Yamada; Masamichi Goto
Journal:  Gut Liver       Date:  2008-12-31       Impact factor: 4.519

4.  MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma.

Authors:  Chanchai Boonla; Banchob Sripa; Peti Thuwajit; Ubon Cha-On; Anucha Puapairoj; Masanao Miwa; Sopit Wongkham
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

5.  Markers of bile duct tumors.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Alessandra Rando; Mario Uccello; Francesco Basile; Antonio Biondi; Santo Carnazzo; Innocenza Alessandria; Clorinda Mazzarino
Journal:  World J Gastrointest Oncol       Date:  2011-04-15

6.  Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection.

Authors:  Kee-Taek Jang; Seung-Mo Hong; Kyu Taek Lee; Jong Gyun Lee; Seoung Ho Choi; Jin Seok Heo; Dong Wook Choi; Dongil Choi; Jae Hoon Lim
Journal:  Virchows Arch       Date:  2008-10-15       Impact factor: 4.064

7.  Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis.

Authors:  Ma Jinfeng; Wataru Kimura; Ichiro Hirai; Fumiaki Sakurai; Toshiyuki Moriya; Masaomi Mizutani
Journal:  Int J Gastrointest Cancer       Date:  2003

8.  Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.

Authors:  Joseph R Francica; Meghan K Matukonis; Paul Bates
Journal:  Virology       Date:  2008-11-14       Impact factor: 3.616

9.  Immunohistochemical Coexpression of MUC1 and MUC4 in Oral Leukoplakia and Oral Squamous Cell Carcinoma.

Authors:  Renu Rathee; Anju Devi; Anjali Narwal; Mala Kamboj; Sunita Singh
Journal:  Head Neck Pathol       Date:  2021-02-05

10.  A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach.

Authors:  Suguru Yonezawa; Shinichi Kitajima; Michiyo Higashi; Masahiko Osako; Michiko Horinouchi; Seiya Yokoyama; Sho Kitamoto; Norishige Yamada; Yukihiro Tamura; Takeshi Shimizu; Mineo Tabata; Masamichi Goto
Journal:  Gastric Cancer       Date:  2012-01-12       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.